Processing your payment...
Please do not close your browser.

Repurposed Drugs Market- Global Growth, Trends and Forecast (2022 - 2029) By Disease Indication {Oncology, CNS Diseases, Neurodegenerative diseases, Other (autoimmune diseases, Leishmaniasis etc.)} and By Regions

28 Jun, 2022 | 98 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Repurposed Drugs Market will register a CAGR of 5.1 % in terms of revenue and the global market size will reach USD 38.1 Billion by 2029.

Repurposed Drugs Market Overview

An overview of the global markets for medication re-purposing (also known as re-positioning or re-profiling), which refers to research that looks at whether a chemical or biologic agent that cures one illness is safe and effective for treating other conditions. Drug repurposing or re-profiling has been the hallmark of good corporate growth, and the majority of pharmaceutical and biopharmaceutical businesses are following the trend. Between a period of 7 years, 30-40% of all biologics authorized in the United States were repurposed or repositioned medications.

Pharmaceutical firms can test a medicine meant to treat one illness to determine whether it can be repurposed to treat another condition using solutions available in the worldwide drug repurposing industry. This can help pharmaceutical companies and researchers save a lot of time and money. When comparing drug repurposing to standard drug development, the cost and time it takes for a medicine to reach the market are drastically lowered because the repurposed drug has already completed a large number of tests.

What is our Repurposed Drugs Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 7.6 % during the review period (2022 to 2029).

 

By Disease Indication

  • Oncology
  • CNS Diseases
  • Neurodegenerative diseases
  • Other (autoimmune diseases, Leishmaniasis, etc.)

 

 

 

By Companies

  • Astellas Pharma Inc.
  • Biovista
  • Novartis AG
  • AbbVie Inc., Pfizer Inc.
  • Allergan Plc.
  • NuMedii
  • others

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

 

Historical Year

 

2017 to 2021

Forecast Year

2022 to 2029

Number of Pages

98

 

Customization Available

 

Yes, the report can be customized as per your needs

Who are the Major Players in Repurposed Drugs Market?

Market Growth Reports list out all the Repurposed Drugs Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Astellas Pharma Inc., Biovista Inc., Novartis AG, AbbVie Inc., Pfizer Inc., Allergan Plc., NuMedii and Others.

Industry News:

Drug Repurposing Market Hitting New Highs By 2030 | Atomwise Inc, Biovista Inc., Centene Corporation

New Jersey, United States-Because repurposed pharmaceuticals need less time to produce than novel chemical entities, and the worldwide drug repurposing market is expanding. Furthermore, developments in the processing capacity to analyze massive databases have enabled cost-effective approaches to medication development. This contributes to the market’s expansion. However, a lack of knowledge of polypharmacological effects of medications, as well as a shortage of educated staff, are limiting market expansion.

What are the major Disease Indication for Repurposed Drugs Market?

By Disease Indication, it is segmented into

  • Oncology
  • CNS Diseases
  • Neurodegenerative diseases
  • Other (autoimmune diseases, Leishmaniasis, etc.)

Repurposed Drugs Market Regional Analysis

The market is broken down into regions, with the competitive landscape for each one described. North America (the United States, Canada, and Mexico), Europe (Germany, France, the United Kingdom, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, and Colombia), the Middle East, and Africa are among the regions discussed in the study (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa). These insights aid in the development of plans and the creation of new chances for achieving outstanding achievements.

 

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    • MARKET DEFINITION
    • MARKET DYNAMICS
    • MARKET SEGMENTATION
    • REPORT TIMELINES
    • KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    • DATA MINING
      • SECONDARY RESEARCH
      • PRIMARY RESEARCH
      • SUBJECT MATTER EXPERT ADVICE
    • QUALITY CHECK
    • FINAL REVIEW
      • DATA TRIANGULATION
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
      • RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    • INTRODUCTION
    • GLOBAL REPURPOSED DRUGS MARKET BY DISEASE INDICATION
  4. MARKET DYNAMICS
    • DRIVERS
      • INCREASING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASE
    • RESTRAINTS
      • STRINGENT ENVIRONMENTAL REGULATIONS
      • HIGH COST OF MATERIALS
    • OPPORTUNITIES
      • REPURPOSED DRUGS GROWTH
    • APPLICATION OF REPURPOSED DRUGS IMPACT ON COVID 19
  5. GLOBAL REPURPOSED DRUGS MARKET, BY DISEASE INDICATION
    • INTRODUCTION
    • ONCOLOGY
    • CNS DISEASES
    • NEURODEGENERATIVE DISEASES
    • OTHER (AUTOIMMUNE DISEASES, LEISHMANIASIS ETC.)
  6. GLOBAL REPURPOSED DRUGS MARKET, BY REGION
    • NORTH AMERICA
      • US
      • CANADA
      • MEXICO
    • EUROPE
      • GERMANY
      • FRANCE
      • UK
      • ITALY
      • RUSSIA
      • REST OF EUROPE
    • APAC
      • CHINA
      • SOUTH KOREA
      • JAPAN
      • INDIA
      • AUSTRALIA
      • ASEAN
      • REST OF APAC
    • MIDDLE EAST AND AFRICA
      • SAUDI ARABIA
      • UAE
      • SOUTH AFRICA
      • TURKEY
      • REST OF MEA
    • SOUTH AMERICA
      • BRAZIL
      • REST OF MEA
      • ARGENTINA
      • REST OF SOUTH AMERICA
  7. COMPETITIVE LANDSCAPE
    • MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    • AND AGREEMENTS
      • KEY DEVELOPMENT
    • MARKET SHARE PERCENT/RANKING ANALYSIS
    • STRATEGIES ADOPTED BY LEADING PLAYERS
  8. COMPANY PROFILES
    • BUSINESS OVERVIEW
    • COMPANY SNAPSHOT
    • PRODUCT BENCHMARKING
    • STRATEGIC INITIATIVES
  1. ASTELLAS PHARMA INC.
  2. BIOVISTA
  3. NOVARTIS AG
  4. ABBVIE INC., PFIZER INC.
  5. ALLERGAN PLC.
  6. NUMERIC
  7. OTHERS

 

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla